Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04752215
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-19
First Post:
2021-02-11
Brief Title:
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-06
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-02-11
First Submit QC Date:
February 11 2021
Study First Post Date:
2021-02-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-23
Last Update Post Date:
2024-03-19
Last Update Post Date Type:
ACTUAL